Home › Mild Cognitive Impairment › NCT07583251

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Who can join

Ages 55 to 80 · All sexes

Inclusion Criteria:

1. Memory complaints;
2. MCI diagnosis
3. MoCA score between 18-25
4. Age 55 - 80 years old.
5. Ability to read and write in English

Exclusion Criteria:

1. Subjects with a history of cancer;
2. Subjects with a history of schizophrenia, manic-depressive disorder
3. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
4. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence;

About the study

The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.

What is being tested

• Gamma- Glutamylcysteine (drug)
• Gamma- Glutamylcysteine (drug)
• Gamma- Glutamylcusteine (drug)

Sponsor: Pravat Mandal · Participants: 9 · Started: Aug 4, 2026

Contact the study team

• Pravat Pravat K MANDAL · Phone: 4126999561
• Nazia Pillar · Phone: 878-670-3123

Official record on ClinicalTrials.gov — NCT07583251

Locations in the U.S.

Conditions

• Mild Cognitive Impairment

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.